NBIX

NASDAQ · Biotechnology

Neurocrine Biosciences Inc

Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks

$139.49

-2.76 (-1.94%)

As of Sep 23, 9:45 PM ET ·

NBIX News2 articles

Soleno Halts European Drug Review Following $2.9B Neurocrine Acquisition

Soleno Therapeutics has withdrawn its European marketing application for VIOKAT, a day after agreeing to a $2.9 billion all-cash acquisition by Neurocrine Biosciences. The move halts a regulatory review previously expected to conclude by mid-2026.

Neurocrine Acquires Soleno in $2.9B Deal for Rare Disease Drug Vykat XR

Neurocrine Biosciences will purchase Soleno Therapeutics in a $2.9 billion all-cash transaction, securing the commercial rights to Vykat XR. The deal offers $53 per share to Soleno stockholders.